A- A A+

Evaluation of an interprofessional naloxone didactic and skills session with medical residents and physician assistant learners.

Hargraves D, White CC, Mauger MR, Puthota A, Pallerla H, Wigle P, Brubaker SL, Schlaudecker JD.

Pharm Pract (Granada). 2019 Jul-Sep;17(3):1591. doi: 10.18549/PharmPract.2019.3.1591.


Naloxon – Medizinische Grundlagen und internationale Erfahrungen / Naloxon – Medical basics and international experience 

Norbert Wodarz, Jörg Wolstein , Heike Wodarz-von Essen und Oliver Pogarell  

SUCHT (2019), 65, pp. 335-342. doi.org/10.1024/0939-5911/a000624



Kanada. Get naloxone – no matter how you choose to consume 

The BC Centre for Disease Control (BCCDC) is advising people who use drugs to get trained in overdose response and pick up a Take Home Naloxone kit, regardless of how they choose to consume, after new research reveals that people who smoke or snort drugs are half as likely to carry life-saving naloxone medication. (BC Centre for Disease Control, Kanada, 23.10.2019)


Kanada. Rapid increase in naloxone distribution after kits became available at Ontario pharmacies 

Almost 68,000 people received a naloxone kit from a pharmacy in the two-year study period. (eurekalert.org, 18.10.2019)


Schottland. Police oppose naloxone overdose kits: 'not our job to save lives'

CAMPAIGNERS calling for Police Scotland officers to carry naloxone – a medication used to block the effects of opiates and save the lives of people overdosing from drugs – have reacted with anger to claims from the Scottish Police Federation that their ask goes beyond the call of duty. (The National, UK, 02.10.2019)


Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone.

Kassick AJ, Allen HN, Yerneni SS, Pary F, Kovaliov M, Cheng C, Pravetoni M, Tomycz ND, Whiting DM, Nelson TL, Feasel M, Campbell PG, Kolber B, Averick S.

ACS Appl Bio Mater. 2019 Aug 19;2(8):3418-3428. doi: 10.1021/acsabm.9b00380. 


Survey of Southern Wisconsin Needle Exchange Clients Regarding Opioid Overdose and Naloxone Use.

Baltes A, Devo B, Kaiser M, Birstler J, Brown RT.

WMJ. 2019 Jul;118(2):84-87. PMID: 31532934


Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Dale O.

Tidsskr Nor Laegeforen. 2019 Sep 23;139(13). doi: 10.4045/tidsskr.19.0162. Print 2019 Sep 24. 


Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Torralva PR, Janowsky A.

J Pharmacol Exp Ther. 2019 Sep 6. pii: jpet.119.258566. doi: 10.1124/jpet.119.258566. 


Bayern zieht positive Bilanz für Modellprojekt mit Naloxon

München – Mit Naloxon kann Heroin- beziehungsweisen Opioidabhängigen bei einem Atemstillstand schnell geholfen werden – seit einem Jahr unterstützt der Freistaat Bayern ein Modellprojekt, bei dem Laien der Umgang mit dem Gegenmittel beigebracht wird. Bayerns Gesundheitsministerin Melanie Huml (CSU) zog vorgestern in München eine positive Bilanz. (aerzteblatt.de, 30.09.2019)


Naloxon: Evaluation der Peer-Informations-Veranstaltungen -- Münster, Februar 2019

Eva Gesigora, Ralf Gerlach 

Institut zur Förderung qualitativer Drogenforschung, akzeptierender Drogenarbeit und rationaler Drogenpolitik (INDRO) e.V.


NYXOID®– Naloxon Nasenspray: Schulungsvideo

Mundipharma, 2019, Video, 05:50


Bayern. Naloxon Take-Home Kits: Schulung Betroffener (und Peers) – ein Modellprojekt in Bayern

N.Wodarz, H. Wodarz-von Essen, j.Wollstein, O.Pogarell

Präsentation auf dem 20. Interdisziplinären Kongress für Sucht-Medizin, 04.07. bis 06.07.2019 in München

Wodarz Take Home Naloxon Modellprojekt Bayern2019.pdf

Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.

Guy GP Jr, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM.

MMWR Morb Mortal Wkly Rep. 2019 Aug 9;68(31):679-686. doi: 10.15585/mmwr.mm6831e1.


Naloxone as a technology of solidarity: history of opioid overdose prevention

Nancy D. Campbell

CMAJ August 26, 2019 191 (34) E945-E946; doi.org/10.1503/cmaj.190257 


USA. Drug Overdose Prevention & Education (DOPE) Project: San Francisco

Currently, the DOPE Project is the largest single-city naloxone distribution program in the country, responsible for training over 13,000 people in San Francisco(with that number growing every day!). People who use drugs, their loved ones, and surrounding community are responsible for reversing on average 1,500 overdoses a year with DOPE Project naloxone. (2019)


EMCDDA. Take-home naloxone

Introduction: What is naloxone and why is it important?

Drug overdose continues to be the main cause of death among problem drug users. Heroin or other opioids — often consumed alongside other central nervous system depressants such as benzodiazepines and alcohol — are present in the majority of reported fatal overdoses (1). Overdose is common among opioid users: many of them have experienced a non-fatal overdose and most have witnessed one. Death from opioid overdose is caused primarily by respiratory depression leading to cardiac arrest.

Opioid overdose deaths can be prevented through timely administration of naloxone, a potent opioid antagonist drug that rapidly reverses the effects of opioid analgesics by binding to the opioid receptors in the central nervous system (see Spotlight: Naloxone). Because of its effectiveness, naloxone is used by emergency personnel worldwide (2). (EMCDDA, Lissabon, August 2019)


USA. Naloxone: Wide distribution effective in preventing deaths

ANN ARBOR—Broad distribution of the opioid reversal drug naloxone is highly cost-effective in reducing fatal overdoses, according to a new University of Michigan study.

The researchers examined the cost-effectiveness of increased distribution of naloxone to laypeople likely to witness or experience overdose, police and firefighters, and emergency medical services. (University of Michigan, USA, 20.08.2019)


The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

Bergeria CL, Huhn AS, Tompkins DA, Bigelow GE, Strain EC, Dunn KE.

Drug Alcohol Depend. 2019 Sep 1;202:111-114. doi: 10.1016/j.drugalcdep.2019.05.010.



Public perceptions of naloxone use in the outpatient setting.

Smith JO, Malinowski SS, Ballou JM.

Ment Health Clin. 2019 Jul 1;9(4):275-279. doi: 10.9740/mhc.2019.07.275.


Narcan or Nar-can't: Tips and Tricks to Safely Reversing Opioid Toxicity.

Li K, Armenian P, Mason J, Grock A.

Ann Emerg Med. 2018 Jul;72(1):9-11. doi: 10.1016/j.annemergmed.2018.05.010.



Vital Signs: Pharmacy-Based Naloxone Dispensing — United States, 2012–2018.

Guy GP Jr., Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. 

MMWR Morb Mortal Wkly Rep 2019;68:679–686. doi.org/10.15585/mmwr.mm6831e1.


Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine

Strang, J., McDonald, R., Campbell, G. et al. 

Drugs (2019). doi.org/10.1007/s40265-019-01154-5


Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment.

Gicquelais RE, Mezuk B, Foxman B, Thomas L, Bohnert ASB.

Harm Reduct J. 2019 Jul 16;16(1):46. doi: 10.1186/s12954-019-0317-3.


Take Home Naloxone: best practice in preventing fatal opioid overdoses for prison leavers

(...) People leaving prison are at the highest risk of overdose and drug-related death in the first weeks following release. This is likely due to reduced tolerance to heroin, increased purity of drugs compared to those used in prison and the tendency of some released prisoners to return to previous drug use patterns.Increasing the uptake of Take Home Naloxone (THN) amongst opioid users leaving prison (and in the community) can help reduce the number of drug-related deaths amongst this high risk population. (The Forward Trust, UK, Pulse#7, Juni 2019)


Pulmonary Complications of Opioid Overdose Treated With Naloxone.

Farkas A, Lynch MJ, Westover R, Giles J, Siripong N, Nalatwad A, Pizon AF, Martin-Gill C.

Ann Emerg Med. 2019 Jun 7. pii: S0196-0644(19)30309-9. doi: 10.1016/j.annemergmed.2019.04.006. 



Naloxone interventions in opioid overdoses: a systematic review protocol.

Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-Waters MM, Brasher PMA, Hau JP, Curran J, Hohl CM.

Syst Rev. 2019 Jun 11;8(1):138. doi: 10.1186/s13643-019-1048-y.


Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.

Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. 

JAMA Netw Open.Published online June 21, 20192(6):e196215. doi:10.1001/jamanetworkopen.2019.6215


Naloxone urban legends and the opioid crisis: what is the role of public health?

Crabtree A, Masuda JR.

BMC Public Health. 2019 May 30;19(1):670. doi: 10.1186/s12889-019-7033-5.


Successful Naloxone Challenge Test in a Patient With Atrial Flutter.

Harlow TR, Peters JR, Anderson DL.

Prim Care Companion CNS Disord. 2019 May 23;21(3). pii: 18l02385. doi: 10.4088/PCC.18l02385.